Mexican Developments to Face COVID-19By Miriam Bello | Thu, 07/16/2020 - 16:55
Organizational difficulties reign in Mexico since the federal government delegated states the responsibility of managing the pandemic. With laxer preventive measures, more cases are reported. Despite this scenario, Mexican academics have successfully worked on developments that favor the country’s conditions to face the virus.
Here is the Week in Health!
-The government has announced an 80 percent international medicine supply following WHO and PAHO guidelines. Leaders of the industry have vocally expressed their concerns and efforts to defend the local pharmaceutical industry. To know more about their opinions, click here.
-The Ministry of Health, alongside CONACYT, announced the launch of two Mexican ventilators Ehécatl 4T and Gätsi, fully developed by Mexicans as a response to the COVID-19 pandemic. During the announcement, CONACYT said that these are affordable, high-quality and biomedically safe devices ready to use in Mexico.
-Every Sunday, the Minister of Health shows a map indicating the progress of Mexican states toward a safe new normality. This past weekend, Deputy Minister of Health Hugo López-Gatell declared that the map would no longer be posted until further notice, as some states had not entered the data correctly. Later on, Minister of Interior Olga Sánchez Cordero called for a meeting with all state governors to clarify and rectify their commitment to transparency and timely delivery of COVID-19 data.
-Mexican pharmaceutical Laboratorios Silanes is running clinical trials on their metformin glycinate molecule, which, because of its characteristics, could positively help with the viral load of the SARS-CoV-2 virus on patients with moderate to severe symptoms. This molecule was originally used to treat diabetes but during its study, the company identified many characteristics that could benefit COVID-19 symptoms.
-Moderna Therapeutics announced positive results for its COVID-19 vaccine this week. According to the company, results of the Phase 1 trials indicate “clear safety and solid immunogenicity.” During phase 1, 45 people received a dose of the vaccine. Phase 2 of the trials, which began in May, consisted of 600 participants and Phase 3, which is expected to begin in July 27, will involve 30,000 people.
-Novartis announced that through its division Sandoz, they would be selling price-production generic medicines to treat COVID-19 symptoms in developing countries.
-COVID-19 vaccine access has been a matter of concern for developing countries. During a press conference, PAHO representative Carissa Etienne explained the mechanism called Cova that the organization will follow to ensure that America, specially the most vulnerable countries of Latin America, can access the vaccine. Cova consist of a regional cooperation fund that intents to bring support to Latin America and the Caribbean expressly regarding the COVID-19 vaccine.